[Evaluation of the survival of bone marrow mononucleate cells transplanted in a rat model of striatal lesion with quinolinic acid].
BACKGROUND
Transplant is one of the alternatives available for the treatment of neurodegenerative diseases aimed at replacing the cells lost during the course of the disease. One promising source of cells for the development of transplants could be the mononucleate cells from bone marrow. AIMS. The purpose of this study was to study the capacity of bone marrow mononucleate cells to survive the transplant process, and to search for a method that enables tracking of these cells in vivo once they have been implanted.


METHODS
Bone marrow mononucleate cells were extracted from the femur of rats by means of a Ficoll-Hypaque gradient. The cells under study were modified genetically with an adenovirus that expresses the PFV or which are marked with Hoechst dye. The marked cells were implanted in the striatum of rats with lesions caused by quinolinic acid.


RESULTS
The viability of the genetically modified cells was low, whereas that of the cells marked with Hoechst dye was above 90%. The implanted cells survived the transplant at least a month and dispersed away from the site of entry towards the corpus callosum and cortex.


CONCLUSIONS
We consider that the use of Hoechst dye offers more advantages for tracking these cells in vivo. Mononucleate cells have a number of characteristics that allow them to be included as candidate sources of cells for the treatment of neurodegenerative diseases.
Alberti-Amador
E
E
Centro Internacional de Restauracion Neurologica (CIREN), Cubanacan, Playa, 11300 Havana, Cuba.
García-Miniet
R
R
Serrano-Sánchez
T
T
Blanco-Lezcano
L
L
Martínez-Marti
L
L
Mendoza-Mari
Y
Y
Rosillo-Martí
J C
JC
Castillo-Díaz
L
L
de la Cuétara-Bernal
K
K
D000818:Animals; D001562:Benzimidazoles / Q000378:metabolism; D001854:Bone Marrow Cells / Q000166:cytology / Q000502:physiology; D016026:Bone Marrow Transplantation; D002465:Cell Movement; D002470:Cell Survival; D005456:Fluorescent Dyes / Q000378:metabolism; D008297:Male; D019636:Neurodegenerative Diseases / Q000628:therapy; D017378:Quinolinic Acid / Q000633:toxicity*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D014793:Visual Cortex / Q000166:cytology / Q000187:drug effects / Q000473:pathology
D001562:Benzimidazoles; D005456:Fluorescent Dyes; D017378:Quinolinic Acid; C017807:bisbenzimide ethoxide trihydrochloride